Smith D, Delaney S, Allain J P, Vallari D, Lee H
Blood Center for Southeast Louisiana, New Orleans.
Transfusion. 1992 Jun;32(5):415-9. doi: 10.1046/j.1537-2995.1992.32592327713.x.
In a pilot study designed to evaluate the performance of supplemental hepatitis C virus (HCV) tests, 146 consecutive HCV enzyme immunoassay (EIA)-reactive samples (0.98% of 14,949 donors) were comparatively evaluated with two sets of supplemental tests: HCV antibody neutralization/c100-3 peptide EIA and the first-generation HCV recombinant immunoblot assay (RIBA). Of these samples, 68.5 percent were positive and 17.8 percent were negative on both supplemental assays. Nineteen samples were discordant. Eleven samples were positive on one assay (9 on neutralization/peptide, 2 on RIBA) and negative or indeterminate on the alternate supplemental test, but reacted with two additional HCV antigens outside the c100-3 region in a second-generation dot immunoblot assay. The dot immunoblot assay was used as a reference and reactive samples were considered confirmed. The remaining eight discordant samples were indeterminate or negative on either assay and did not react on the dot immunoblot assay. These data indicate a 0.74-percent prevalence of HCV exposure detected by reactivity with the c100-3 antigen in blood donors in southern Louisiana.
在一项旨在评估丙型肝炎病毒（HCV）补充检测性能的初步研究中，对146份连续的HCV酶免疫测定（EIA）反应性样本（占14949名献血者的0.98%），用两组补充检测进行了比较评估：HCV抗体中和/c100 - 3肽EIA和第一代HCV重组免疫印迹分析（RIBA）。在这些样本中，68.5%在两种补充检测中均为阳性，17.8%在两种补充检测中均为阴性。19份样本结果不一致。11份样本在一种检测中为阳性（9份在中和/肽检测中，2份在RIBA检测中），而在另一种补充检测中为阴性或不确定，但在第二代斑点免疫印迹分析中与c100 - 3区域外的另外两种HCV抗原发生反应。斑点免疫印迹分析用作参考，反应性样本被视为确诊。其余8份不一致的样本在任何一种检测中均为不确定或阴性，且在斑点免疫印迹分析中无反应。这些数据表明，路易斯安那州南部献血者中，与c100 - 3抗原反应检测到的HCV暴露患病率为0.74%。
